New drug combo aims to reduce surgeries for rare HPV throat condition
NCT ID NCT04645602
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests two cancer drugs—lenvatinib (a daily pill) and pembrolizumab (an IV infusion)—in 20 adults with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink papillomas and reduce how often patients need surgery to clear their airways. The trial also monitors safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib (Lenvima) and pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a drug treatment that reduces or eliminates the need for repeated surgeries to remove papillomas from the airways and lungs.
What could go wrong
This is a very early, small pilot study with only 20 people. The combination may cause significant side effects, and there is no guarantee it will shrink tumors or improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact